Epicrispr Biotechnologies

CRISPR Therapeutics AG (CRSP) is a biotechnology firm dedicated to pioneering gene-based medicines for severe diseases. The company achieves this through its exclusive Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) technology, which enables precise and targeted alterations to an organism's genetic code. Its extensive pipeline includes therapeutic candidates spanning multiple medical areas, such as blood disorders (hemoglobinopathies), various cancers (oncology), regenerative medicine, and rare conditions. The company's flagship investigational therapy is CTX001, an ex vivo CRISPR gene-edited treatment. This therapy aims to benefit patients with transfusion-dependent beta-thalassemia or severe sickle cell disease by modifying their own hematopoietic stem cells to markedly boost the production of fetal hemoglobin within red blood cells. CRISPR Therapeutics is also advancing several other genetically engineered allogeneic (donor-sourced) CAR-T investigational therapies: CTX110, designed to combat cluster of differentiation 19-positive malignancies; CTX120, which targets B-cell maturation antigen for multiple myeloma that has relapsed or proven resistant to previous treatments; and CTX130, focused on Cluster of Differentiation 70 for a spectrum of solid tumors and blood cancers. Furthermore, the company is developing VCTX210, an immune-evasive, gene-edited stem cell-derived product candidate for treating type 1 diabetes. It is also pursuing various in vivo gene-editing initiatives aimed at addressing disorders affecting the liver, lungs, muscles, and central nervous system. The company has forged strategic alliances with significant partners, including Bayer Healthcare LLC, Vertex Pharmaceuticals Incorporated, ViaCyte, Inc., Nkarta, Inc., and Capsida Biotherapeutics. CRISPR Therapeutics AG was established in 2013 and maintains its headquarters in Zug, Switzerland.

EVOPOINT BIOSCIENCES CO.,LTD.688837 · BiotechChina

71% matchPublic

EVOPOINT BIOSCIENCES CO., LTD. is an innovation-driven pharmaceutical company that focuses on precision oncology, multi-drug resistant bacterial infections, and metabolic diseases. Utilizing core platforms such as small molecule targeted drug development, complex antibody drug development, and targeted protein degradation, the company researches and develops innovative drug pipelines to provide treatment solutions for patients globally.

SNIPR Biome is a clinical-stage life sciences company headquartered in Copenhagen, Denmark, pioneering precision medicines and CRISPR-guided technologies for difficult-to-treat conditions.

Base Therapeutics is a biotechnology company that develops next-generation gene editing technologies, including its proprietary AccuBase base editing system and enhanced prime editing technology. The company focuses on creating therapeutic solutions for cancer and genetic diseases, alongside engineered immune cell therapies such as BASE-NK and CAR-T products. It serves patients and partners with pharmaceutical and agricultural enterprises by licensing its precision gene editing tools.

Arbor Biotechnologies, Inc.BiotechnologyUnited States

70% matchPrivate

Arbor Biotechnologies, Inc. is a next-generation gene editing company focused on discovering and developing precise genetic medicines for rare and complex diseases.

YolTech Therapeutics is a clinical-stage biotechnology company that specializes in developing in vivo gene editing therapies and mRNA drugs for serious diseases. The company utilizes novel CRISPR-Cas enzymes, base editors, and lipid nanoparticle delivery systems to create precision genetic medicines.